CTSO

CytoSorbents Corporation develops and commercializes medical devices that utilize its proprietary adsorption technology to manage critical conditions in various clinical settings. Its primary product, CytoSorb®, is designed to remove harmful cytokines and other inflammatory mediators from blood during procedures such as cardiac surgery. The company also offers PuriFi for hemoperfusion procedures and ECOS for ex vivo organ perfusion. CytoSorbents serves healthcare providers globally, focusing on critical care and surgical markets.